FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

787732000: Risankizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3776694016 Risankizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3776695015 Risankizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5593121000241115 risankizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Risankizumab Is a Substance with interleukin 23 receptor antagonist mechanism of action (substance) true Inferred relationship Some
Risankizumab This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Interleukin 23 receptor antagonist (disposition) true Inferred relationship Some
Risankizumab Is a anticorps monoclonal chimérique souris-humain d'isotype IgG false Inferred relationship Some
Risankizumab Is a Immunosuppressant (substance) true Inferred relationship Some
Risankizumab Is a Monoclonal antibody false Inferred relationship Some
Risankizumab Is a Monoclonal immunoglobulin G (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing risankizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Risankizumab Inferred relationship Some 1
Risankizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Risankizumab Inferred relationship Some 1
Risankizumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Risankizumab Inferred relationship Some 1
Risankizumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Risankizumab Inferred relationship Some 1
Risankizumab 150 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Risankizumab Inferred relationship Some 1
Risankizumab 150 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Risankizumab Inferred relationship Some 1
Product containing precisely risankizumab 90.361 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Risankizumab Inferred relationship Some 1
Product containing precisely risankizumab 90.361 milligram/1 milliliter conventional release solution for injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Risankizumab Inferred relationship Some 1
Risankizumab therapy (procedure) Direct substance True Risankizumab Inferred relationship Some 1

This concept is not in any reference sets

Back to Start